| Current Price | $49.61 | Mkt Cap | $7.2B |
|---|---|---|---|
| Open | $50.12 | P/E Ratio | -17.45 |
| Prev. Close | $49.94 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $49.33 - $50.12 | Volume | 359,731 |
| 52-Wk Range | $32.69 - $51.89 | Avg. Daily Vol. | 1,120,806 |
The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.
| Current Price | $49.61 | Mkt Cap | $7.2B |
|---|---|---|---|
| Open | $50.12 | P/E Ratio | -17.45 |
| Prev. Close | $49.94 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $49.33 - $50.12 | Volume | 359,731 |
| 52-Wk Range | $32.69 - $51.89 | Avg. Daily Vol. | 1,120,806 |
The best Bull and Bear pitches based on recency and number of recommendations.
Ionis has several candidates in the pipeline and expects to have at least 12 commercialized products by 2026. If that happens, we can expect a big increase in revenue over the coming years.
This biotech pharma company has out performed the S&P 500 over the last 10 years by hundreds of percent, but over the last 5 years, IONS has lost to the market by almost 30%, with most of those losses coming in 2020. The Founders are still involved,… More
Read the most recent pitches from players about IONS.
Recs
TMFAdriaCimino
(< 20)
Submitted: 7/3/2021 6:07:34 PM :
Start Price:
$40.22
NASDAQ:IONS Score:
+18.22
Ionis has several candidates in the pipeline and expects to have at least 12 commercialized products by 2026. If that happens, we can expect a big increase in revenue over the coming years.
Recs
MKWas
(< 20)
Submitted: 2/18/2021 3:01:53 PM :
Start Price:
$57.84
NASDAQ:IONS Score:
-31.04
A leaders in antisense oligonucleotides, an emerging technology used to control messenger RNA .
Recs
IndyAnthony
(< 20)
Submitted: 2/5/2021 11:57:00 PM :
Start Price:
$60.59
NASDAQ:IONS Score:
+35.50
This biotech pharma company has out performed the S&P 500 over the last 10 years by hundreds of percent, but over the last 5 years, IONS has lost to the market by almost 30%, with most of those losses coming in 2020. The Founders are still involved, but institutions own almost 87% of the company. Despite collaborations with Roche, Biogen, and AstraZeneca, I think this company will underperform the market over the next 5-10 years.
Find the members with the highest scoring picks in IONS.
yosemitebean (< 20) Score: +638.02
The Score Leader is the player with the highest score across all their picks in IONS.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| RXDOC73 | 98.02 |
|
|
NS | $6.59 | +655.99% | +283.82% | +372.17 | 1 Comment | |
| Myshkin69 | < 20 | 11/14/2011 |
|
5Y | $6.99 | +612.73% | +265.23% | +347.51 | 0 Comment | |
| loangolfer | < 20 |
|
|
NS | $6.99 | +612.73% | +265.98% | +346.75 | 0 Comment | |
| Santa22 | < 20 | 9/22/2006 |
|
3Y | $7.02 | +609.69% | +270.60% | +339.08 | 0 Comment | |
| asterionc2 | 79.75 | 9/27/2006 |
|
5Y | $7.10 | +601.69% | +264.60% | +337.09 | 0 Comment | |
| jdmckeehan | < 20 | 10/2/2006 |
|
3Y | $7.18 | +593.87% | +264.33% | +329.54 | 0 Comment | |
| leadtip | < 20 | 8/25/2006 |
|
1Y | $7.09 | +602.68% | +277.05% | +325.63 | 0 Comment | |
| John8464 | < 20 | 9/15/2006 |
|
1Y | $7.23 | +589.07% | +266.46% | +322.62 | 0 Comment | |
| gsstock | < 20 | 8/23/2006 |
|
5Y | $7.14 | +597.76% | +275.20% | +322.56 | 0 Comment | |
| schmosly | < 20 | 10/3/2006 |
|
1Y | $7.31 | +581.53% | +264.53% | +317.00 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
